A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

[1]  M. Lacouture,et al.  Increased risk of high‐grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy , 2009, Cancer.

[2]  M. Lacouture,et al.  Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials. , 2008, Clinical colorectal cancer.

[3]  T. Fojo,et al.  Is there room for improvement in adverse event reporting in the era of targeted therapies? , 2008, Journal of the National Cancer Institute.

[4]  A. Rademaker,et al.  Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.

[5]  Ethan Basch,et al.  Patient-reported outcomes and the evolution of adverse event reporting in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jeffery T. Sloan,et al.  Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Shaw,et al.  Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Lacouture,et al.  Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. , 2007, Oncology.

[9]  S. Bentzen,et al.  Evaluation of early and late toxicities in chemoradiation trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Basti.  Ocular Toxicities of Epidermal Growth Factor Receptor Inhibitors and Their Management , 2007, Cancer nursing.

[11]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Fox.  Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. , 2007, Journal of the American Academy of Dermatology.

[13]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[14]  M. Lacouture.  Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.

[15]  E. Roé,et al.  Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. , 2006, Journal of the American Academy of Dermatology.

[16]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Perez-soler,et al.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[19]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[20]  Jerry Shapiro,et al.  Alopecia areata investigational assessment guidelines-Part II , 2004 .

[21]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[22]  R. Baran.  A nail psoriasis severity index , 2004, The British journal of dermatology.

[23]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[24]  A. Halpern,et al.  Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 , 2001, The British journal of dermatology.